Winkler J D, Thermos K, Weiss B
Psychopharmacology (Berl). 1987;92(3):285-91. doi: 10.1007/BF00210832.
Fluphenazine-N-mustard (FNM) has been shown to irreversibly block dopaminergic receptor sites and inhibit certain dopaminergically-mediated behaviors. In this study we measured whether FNM has any differential effects on D1 and D2 dopaminergic events. Accordingly, we examined the relative effects of FNM on rotational behavior induced by SKF 38393 (D1 agonist) and Ly 171555 (D2 agonist) in mice with unilateral, 6-hydroxydopamine-induced lesions of the striatum and the effects of FNM on the binding of [3H]Sch 23390 (D1 ligand) and [3H]spiroperidol (D2 ligand) to mouse striatal membranes. FNM inhibited rotational behavior induced by Ly 171555 at doses 10-fold lower than those required to block rotations induced by SKF 38393 (ID50 values: Ly 171555 = 1.8 mumole/kg, IP; SKF 38393 = 16 mumole/kg, IP). The inhibitory effect of high doses of FNM (20 mumole/kg) on rotational behavior was overcome by increasing the dose of SKF 38393 and apomorphine, a nonselective dopaminergic agonist. By contrast, the inhibitory effect of FNM was not overcome by Ly 171555, even when given in doses more than 100 times its ED50. Using striatal homogenates in vitro, FNM inhibited the specific binding of [3H]spiroperidol at concentrations about 10-fold lower than those required to inhibit the binding of [3H]Sch 23390 (IC50 values: [3H]spiroperidol = 90 nM; [3H]Sch 23390 = 840 nM). Considerably higher concentrations of FNM were needed to irreversibly inhibit calmodulin activity in striatal homogenates (IC50 = 10 microM).(ABSTRACT TRUNCATED AT 250 WORDS)
氟奋乃静氮芥(FNM)已被证明能不可逆地阻断多巴胺能受体位点并抑制某些多巴胺能介导的行为。在本研究中,我们测定了FNM对D1和D2多巴胺能事件是否有任何差异效应。因此,我们研究了FNM对单侧6-羟基多巴胺诱导纹状体损伤小鼠中由SKF 38393(D1激动剂)和Ly 171555(D2激动剂)诱导的旋转行为的相对影响,以及FNM对[3H]Sch 23390(D1配体)和[3H]螺哌啶醇(D2配体)与小鼠纹状体膜结合的影响。FNM抑制Ly 171555诱导的旋转行为的剂量比阻断SKF 38393诱导的旋转所需剂量低10倍(半数抑制剂量值:Ly 171555 = 1.8微摩尔/千克,腹腔注射;SKF 38393 = 16微摩尔/千克,腹腔注射)。通过增加SKF 38393和阿扑吗啡(一种非选择性多巴胺能激动剂)的剂量,可克服高剂量FNM(20微摩尔/千克)对旋转行为的抑制作用。相比之下,即使给予超过其半数有效剂量100倍的Ly 171555,也无法克服FNM的抑制作用。在体外使用纹状体匀浆时,FNM抑制[3H]螺哌啶醇特异性结合的浓度比抑制[3H]Sch 23390结合所需浓度低约10倍(半数抑制浓度值:[3H]螺哌啶醇 = 9纳米;[3H]Sch 23390 = 八百四十纳米)。需要相当高浓度的FNM才能不可逆地抑制纹状体匀浆中的钙调蛋白活性(半数抑制浓度 = 10微摩尔)。(摘要截短于250字)